Life is hectic, and juggling dozens of apps for the "must-do" chores adds to the noise. Since I already work in Excel daily, ...

Most Excel users spend their time navigating ribbons, building formulas, and formatting cells, all while completely ignoring the status bar at the bottom of the window. It sits there quietly, doing ...

A schematic illustration of how GigTIME can take a hematoxylin and eosin (H&E) pathology slide and use AI to virtually identify a suite of proteins that would otherwise require multiplex ...

Bitcoin enters December with a historically mixed track record, often characterized by sharp outliers and erratic flows. Analyst Daan Crypto notes that recent years have been relatively muted, but the ...

When Steelers coach Mike Tomlin disclosed on Sunday morning that quarterback Aaron Rodgers would not play in his Soldier Field swan song, Tomlin made it clear that he expects Rodgers to return for ...

ABSTRACT: For policymakers involved in land use decision-making, improving knowledge about the expected future soil erosion risk, accelerated by human activities and climate change, is critical.

For weeks, biotech investors have been bracing for the results of a large, late-stage trial of Agios Pharmaceuticals Pyrukynd pill in patients with sickle cell disease.

Shares of Agios Pharmaceuticals (AGIO) plunged ~45% in the premarket on Wednesday after the biotech announced a mixed outcome from a late-stage trial for its lead asset mitapivat in sickle cell ...

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its commercial outlook and the company’s reinvention. Uptake for the genetic ...

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. Down the line, Adagene could make up to $840 million in development and commercial ...